In the latest trading session,, 1.1 million TG Therapeutics Inc (NASDAQ:TGTX) shares changed hands as the company’s beta touched 2.12. With the company’s most recent per share price at $32.40 changed hands at -$3.13 or -8.81% at last look, the market valuation stands at $5.09B. TGTX’s current price is a discount, trading about -33.7% off its 52-week high of $43.32. The share price had its 52-week low at $12.93, which suggests the last value was 60.09% up since then. When we look at TG Therapeutics Inc’s average trading volume, we note the 10-day average is 2.83 million shares, with the 3-month average coming to 2.70 million.
Analysts gave the TG Therapeutics Inc (TGTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.38. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended TGTX as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. TG Therapeutics Inc’s EPS for the current quarter is expected to be 0.16.
TG Therapeutics Inc (NASDAQ:TGTX) trade information
Instantly TGTX was in red as seen in intraday trades today. With action -18.63%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 7.64%, with the 5-day performance at -18.63% in the red. However, in the 30-day time frame, TG Therapeutics Inc (NASDAQ:TGTX) is -13.72% down. Looking at the short shares, we see there were 26.23 million shares sold at short interest cover period of 7.84 days.
The consensus price target for the stock as assigned by Wall Street analysts is 27.5, meaning bulls need a downside of -17.82% from its recent market value. According to analyst projections, TGTX’s forecast low is 27.5 with 27.5 as the target high. To hit the forecast high, the stock’s price needs a 15.12% surge from its current level, while the stock would need to tank 15.12% for it to hit the projected low.
TG Therapeutics Inc (TGTX) estimates and forecasts
Year-over-year growth is forecast to reach 68.25% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 117.07M. 6 analysts are of the opinion that TG Therapeutics Inc’s revenue for the current quarter will be 130.24M. The company’s revenue for the corresponding quarters a year ago was 63.47M and 73.47M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 84.44%. The estimates for the next quarter sales put growth at 77.29%. The 2025 estimates are for TG Therapeutics Inc earnings to increase by 545.38%, but the outlook for the next 5-year period is at 156.15% per year.
TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.38% of TG Therapeutics Inc shares while 62.73% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 69.22%. There are 62.73% institutions holding the TG Therapeutics Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 9.3645% of the shares, roughly 13.69 million TGTX shares worth $243.58 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.8688% or 11.39 million shares worth $202.6 million as of 2024-06-30.
Among Mutual Funds, the top two as of Feb 28, 2025 were iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 8.51 shares estimated at $269.94 million under it, the former controlled 5.42% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.76% of the shares, roughly 4.33 shares worth around $137.5 million.
